These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
765 related articles for article (PubMed ID: 28130774)
1. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns. Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774 [TBL] [Abstract][Full Text] [Related]
2. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States. Adams JL; Shelley K; Nicol MR Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960 [TBL] [Abstract][Full Text] [Related]
3. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection. Trang TP; Dong BJ; Kojima N; Klausner JD Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203 [TBL] [Abstract][Full Text] [Related]
4. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. Mugwanya KK; Baeten JM Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852 [TBL] [Abstract][Full Text] [Related]
5. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes. Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199 [TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report. Malahleha M; Ahmed K; Deese J; Nanda K; van Damme L; De Baetselier I; Burnett RJ J Med Case Rep; 2015 Sep; 9():207. PubMed ID: 26411737 [TBL] [Abstract][Full Text] [Related]
7. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Krakower DS; Mayer KH Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022 [TBL] [Abstract][Full Text] [Related]
8. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803 [TBL] [Abstract][Full Text] [Related]
9. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review. Murewanhema G; Malisheni M; Takah NF Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226 [TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L; Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274 [TBL] [Abstract][Full Text] [Related]
11. Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection. Stalter RM; Pintye J; Mugwanya KK Expert Opin Drug Saf; 2021 Nov; 20(11):1367-1373. PubMed ID: 33998936 [No Abstract] [Full Text] [Related]
12. Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women. Mugwanya KK; John-Stewart G; Baeten J Expert Opin Drug Saf; 2017 Jul; 16(7):867-871. PubMed ID: 28571500 [TBL] [Abstract][Full Text] [Related]
13. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force. Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746 [TBL] [Abstract][Full Text] [Related]
14. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. McCormack S; Dunn DT; Desai M; Dolling DI; Gafos M; Gilson R; Sullivan AK; Clarke A; Reeves I; Schembri G; Mackie N; Bowman C; Lacey CJ; Apea V; Brady M; Fox J; Taylor S; Antonucci S; Khoo SH; Rooney J; Nardone A; Fisher M; McOwan A; Phillips AN; Johnson AM; Gazzard B; Gill ON Lancet; 2016 Jan; 387(10013):53-60. PubMed ID: 26364263 [TBL] [Abstract][Full Text] [Related]
15. MOVING FORWARD WITH PrEP. THE BASICS OF PrEP. Highleyman L Posit Aware; 2015; 27(5):2-3. PubMed ID: 26714333 [No Abstract] [Full Text] [Related]
16. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate. Baum MM; Butkyavichene I; Churchman SA; Lopez G; Miller CS; Smith TJ; Moss JA Int J Pharm; 2015 Nov; 495(1):579-587. PubMed ID: 26386138 [TBL] [Abstract][Full Text] [Related]
17. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K; Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265 [TBL] [Abstract][Full Text] [Related]
18. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? Parikh UM; Mellors JW Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640 [TBL] [Abstract][Full Text] [Related]
19. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France. Noret M; Balavoine S; Pintado C; Siguier M; Brun A; Bauer R; Loze B; Leplatois A; Aslan A; Moudachirou K; Delaugerre C; Rozenbaum W; Molina JM AIDS; 2018 Sep; 32(15):2161-2169. PubMed ID: 30212403 [TBL] [Abstract][Full Text] [Related]
20. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption. Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]